RecruitingAtopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Eligible age
18–100 yrs
Accepts
All genders
Locations
13 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Sponsor: Novartis Pharmaceuticals
Where it's recruiting
Alabama
Birmingham
Arkansas
Fort Smith
California
Fountain Valley · Los Angeles · Sacramento · Santa Ana …
District of Columbia
Washington D.C.
Florida
Miami · St. Petersburg
Georgia
Atlanta · Macon
Kentucky
Louisville
Massachusetts
Brighton
Michigan
Troy
Missouri
Saint Joseph
New Hampshire
Portsmouth
New York
Brooklyn
Source: ClinicalTrials.gov · NCT06947993 · last updated 2026-08-19